Effects of Low-Dose Interleukin-2 on Immune System in Cancer Patients
Author Information
Author(s): L.T. Vlasveld, A. Hekman, F.A. Vyth-Dreesel, E.M. Rankin, J.G.M. Scharenberg, A.C. Voordouw, J.J. Sein, T.A.M. Dellemijn, S. Rodenhuis, C.J.M. Melief
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Does prolonged continuous infusion of low-dose recombinant interleukin-2 enhance immune responses in patients with melanoma and renal cell cancer?
Conclusion
Prolonged low-dose interleukin-2 treatment significantly increases natural killer cell activity without activating T cells.
Supporting Evidence
- Natural killer cells increased significantly during treatment.
- Patients showed enhanced cytotoxic capacity of peripheral lymphocytes.
- No consistent signs of T cell activation were observed.
- Treatment duration ranged from 5 to 18 weeks.
- Patients were treated on an out-patient basis.
Takeaway
This study shows that giving a low dose of a medicine called interleukin-2 for a long time can help boost certain immune cells that fight cancer.
Methodology
Patients received continuous low-dose interleukin-2 infusion for 5 to 18 weeks, and their immune responses were monitored.
Limitations
The study involved a small number of patients and lacked a control group.
Participant Demographics
13 patients (6 male, 7 female), mean age 52 years (range 40-64), with melanoma and renal cell cancer.
Want to read the original?
Access the complete publication on the publisher's website